Seth D, Shaw K, Jazayeri J, Leedman P J
University Department of Medicine, Royal Perth Hospital, Western Australia, Australia.
Br J Cancer. 1999 May;80(5-6):657-69. doi: 10.1038/sj.bjc.6690407.
The epidermal growth factor receptor (EGFR) plays an important role in the development and progression of prostate cancer and its overexpression is associated with decreased survival. With progression, prostate cancer cells switch from epidermal growth factor (EGF) to transforming growth factor alpha (TGF-alpha) synthesis, which contributes to autocrine growth and unrestrained proliferation. To define the molecular mechanisms involved in the regulation of EGFR expression by EGF and TGF-alpha we studied three human prostate cancer cell lines, androgen-responsive (LNCaP) and -unresponsive (DU145 and PC3). Here we show that TGF-alpha stabilized EGFR mRNA two- to threefold in all three cell lines, whilst EGF stabilized EGFR mRNA approximately twofold in LNCaP and DU145 cells, but not in PC3 cells. Both ligands increased EGFR transcription in LNCaP and DU145 cells, with less effect in PC3 cells. In all three cell lines EGF reduced total EGFR protein levels more than TGF-alpha, but this was associated with a greater increase in de novo protein synthesis with EGF compared to TGF-alpha. Only EGF, however, shortened EGFR protein stability (half-life decreased from 5 h to 120 min), resulting in rapid disappearance of newly synthesized EGFR protein. Both ligands increased total LNCaP and DU145 cell numbers. These studies demonstrate that the EGF- and TGF-alpha-induced upregulation of EGFR mRNA and protein in human prostate cancer cell lines is complex and occurs at multiple, transcriptional and post-transcriptional levels. Taken together, these data provide novel insight into the molecular mechanisms by which TGF-alpha would preferentially maintain an autocrine loop in human prostate cancer cells. Furthermore, this work suggests that in human prostate cancer cells ligand-specific differential intracellular trafficking of the EGFR plays a major role in regulating its expression.
表皮生长因子受体(EGFR)在前列腺癌的发生和发展中起重要作用,其过度表达与生存率降低有关。随着病情进展,前列腺癌细胞从合成表皮生长因子(EGF)转变为合成转化生长因子α(TGF-α),这有助于自分泌生长和无节制增殖。为了确定EGF和TGF-α调控EGFR表达所涉及的分子机制,我们研究了三种人前列腺癌细胞系,即雄激素反应性(LNCaP)和非反应性(DU145和PC3)细胞系。在此我们表明,TGF-α使所有三种细胞系中的EGFR mRNA稳定两到三倍,而EGF使LNCaP和DU145细胞中的EGFR mRNA稳定约两倍,但在PC3细胞中则不然。两种配体均增加LNCaP和DU145细胞中的EGFR转录,对PC3细胞的影响较小。在所有三种细胞系中,EGF降低总EGFR蛋白水平的程度超过TGF-α,但这与EGF相比TGF-α引起的从头蛋白质合成增加幅度更大有关。然而,只有EGF缩短了EGFR蛋白稳定性(半衰期从5小时降至120分钟),导致新合成的EGFR蛋白迅速消失。两种配体均增加了LNCaP和DU145细胞的总数。这些研究表明,EGF和TGF-α诱导的人前列腺癌细胞系中EGFR mRNA和蛋白的上调是复杂的,且发生在多个转录和转录后水平。综上所述,这些数据为TGF-α在人前列腺癌细胞中优先维持自分泌环的分子机制提供了新的见解。此外,这项工作表明,在人前列腺癌细胞中,EGFR的配体特异性差异细胞内运输在调节其表达中起主要作用。